Arabic Arabic English English French French German German

Pre-treatment levels of ctDNA may be useful in future clinical trials to predict long-term survival

Pre-treatment circulating tumor (ct)DNA levels more accurately predicted long-term survival than classical survival surrogates in the NADIM study and might be useful for the design of new clinical trials, according to research presented today at the IASLC 2021 World Conference on Lung Cancer. The study was presented in today’s OA20: Exploring Treatment Modalities and Tools in Locally Advanced NSCLC. Read More

Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

Exploring the impact of blood clots in the veins during renal cell carcinoma surgery

Next Post

Immune checkpoint inhibitors convey survival benefit in elderly patients with stage IV non-small cell lung cancer

Related Posts